Stock Price Quote

MARKSANS PHARMA LTD.

NSE : MARKSANSBSE : 524404ISIN CODE : INE750C01026Industry : Pharmaceuticals & DrugsHouse : Private
BSE277.30-3.95 (-1.4 %)
PREV CLOSE ( ) 281.25
OPEN PRICE ( ) 282.70
BID PRICE (QTY) 277.35 (132)
OFFER PRICE (QTY) 277.55 (11)
VOLUME 344705
TODAY'S LOW / HIGH ( )272.10 289.00
52 WK LOW / HIGH ( )97.6 298.7
NSE278.09-3.13 (-1.11 %)
PREV CLOSE( ) 281.22
OPEN PRICE ( ) 282.45
BID PRICE (QTY) 278.09 (5)
OFFER PRICE (QTY) 278.12 (2)
VOLUME 2687206
TODAY'S LOW / HIGH( ) 271.35 289.01
52 WK LOW / HIGH ( )97.45 298.94
BSE NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1992
Management Info
Mark Saldanha - Chairman Mark Saldanha - Managing Director
Registered Office

Address 11th Floor, " Grandeur " Opp. Gundecha Symphony,Veera Desai Extension Road,Oshiwara, Andheri (West),
Mumbai,
Maharashtra-400053

Phone 022- 40012000

Email info@marksanspharma.com

Website www.marksanspharma.com

Registrars Details
Bigshare Services Pvt Ltd
Office No S6-2, 6th Floor, Pinnacle Business Park,Next to Ahura Centre, Mahakali Caves Road,Andheri (E),Mumbai
 Listing : BSE, NSE

NEWS

04Sep Marksans Pharma informs about newspape
Pursuant to Regulation 47 of the Securities and Exchange Board of India..
21Aug Marksans Pharma’s arm secures marketin
Marksans Pharma’s wholly owned subsidiary -- Relonchem has received Mark..
21Aug Marksans Pharma soars after its arm se
Marksans Pharma is currently trading at Rs. 223.30, up by 2.40 points or..
21Aug Marksans Pharma informs about press re
Marksans Pharma has informed that it enclosed press release titled ‘Mark..
20Aug USFDA issues EIR for Marksans Pharma’s
The USFDA has issued an Establishment Inspection Report (EIR) for the ma..
MORE

Financials

in Millions
QTR Jun 24 ANNUAL 24
Net Profit320.151337.58
Gross Profit 422.99 1718.92
Operating Profit 494.182020.08
Net Sales 2545.278532.73
MORE

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  28049.75 (0.91%)
M.Cap ( in Cr)59399.87
Ajanta Pharma (BSE)
peergroup  3183.20 (1.92%)
M.Cap ( in Cr)39905.04
Suven Pharma (BSE)
peergroup  1192.80 (4.18%)
M.Cap ( in Cr)31336.95
Concord Biotech (BSE)
peergroup  2225.70 (1.85%)
M.Cap ( in Cr)23277.11
Alkem Laboratories (BSE)
peergroup  6128.75 (0.61%)
M.Cap ( in Cr)73233.56
MORE

Shareholding Pattern

PROMOTERS 43.87%
NON-INSTITUTION 33.78%
MUTUAL FUNDS/UTI 2.82%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%
MORE

About Marksans Pharma Ltd.

Marksans Pharma Ltd. was incorporated in the year 1992. Its today's share price is 277.3. Its current market capitalisation stands at Rs 12448.41 Cr. In the latest quarter, company has reported Gross Sales of Rs. 8555.08 Cr and Total Income of Rs.9153.46 Cr. The company's management includes Harshavardhan Panigrahi, Sunny Sharma, Shailaja Vardhan, Abhinna Sundar Mohanty, Digant Mahesh Parikh, Seetharama Raju Buddharaju, Varddhman Vikramaditya Jain, Sandra Saldanha, Mark Saldanha, Mark Saldanha.

It is listed on the BSE with a BSE Code of 524404 , NSE with an NSE Symbol of MARKSANS and ISIN of INE750C01026. It's Registered office is at 11th Floor, " Grandeur " Opp. Gundecha Symphony,Veera Desai Extension Road,Oshiwara, Andheri (West)Mumbai-400053, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Bhuta Shah & Co LLP, MSKA & Associates, NK Mittal & Associates, VS Lalpuria & Co

download beyond app
download beyond app
About Nirmal Bang About Nirmal Bang Awards & Accolades Careers at Nirmal Bang Contact Nirmal BangContact Dp Support Contact Trading Support
Product & Services Equity & Derivatives Trading Forex Trading Commodity Trading Institutional Broking Depository Services Loan Against Securities (LAS) Algo Trading
Equity Price Analysis Volume Analysis Index Analysis News Analysis Corporate Action India Market Other Market Share Market Holidays T+1 Settlement securities
Derivatives Updates Market Report Overview
IPO IPO Issues Performance News & Analysis
Commodities Market Movers News & Commentary MCX / NCDEX HolidaysMCX Data feed product and Charges
Portfolio Management Service (PMS) NBSPL - PMS Disclosure Nirmal Bang PMS - Investor Charter SCORES complaints – August 2024 Online Grievance Portal – SCORES Online Dispute Resolution Portal – ODR Contact Us
Mutual Funds About Nirmal Bang Niveshalaya Why Associate with Nirmal Bang Mutual Fund Login Mutual Fund Register FAQs Mutual Fund Holidays SIP Calculator Mutual Funds Updates Mutual Funds Trends Mutual Fund Reports Mutual Fund Terms & Conditions Mutual Privacy Policy
NPS NPS Forms and Guidelines NPS-AML Policy
Nirmal Bang Research Technical Calls Equity Reports Commodity Reports Currency Research Institutional Research
Nirmal Bang Media Knowledge Center Blog Support Center Become A Partner Beyond Market Careers Sitemap Do's And Dont'sInvestor Complaint Data Important Update
Other Links Disclaimer Privacy Policy Terms Of Use Rules & Regulations Disclosures Risk Disclosure Grievances NPS Grievance Policy SEBI ScoresRMS Policy Inspection CSR Committee CSR Policy
CSR Activities
FY-2020-2021 FY-2021-2022 FY-2022-2023 FY-2023-2024
Investor Charter
Linked content_Investor Charter for Depositories and DPs Investor Charter for Depositories and DPs Investor Charter for Stock Broker Investor Charter for Research Investor Complaints -RA Investor Complaints-NBEPL
Evoting
NSDL Evoting CDSL Evoting
Client Bank Account list Smartodr Login Investor Grievance Flow Registered AP’sSurrendered List of AP’sKYC Activation Process Voluntary Freezing Blocking of Online Trading Account Internal Shortage Policy
Connect with Us
ATTENTION INVESTORS Depository IPO KYC Investor Guide
Inactive account treatmentNBSPL Policy of AMLNBEPL Policy of AMLNBSPL CSR Policy Physical Settlement Policy of Derivative Aadhar UpdationNirmalbang Privacy Policy V1.0 Documents in Vernacular Languages NBSPL PMS Disclosure Document
Nirmal Bang Securities Pvt. Ltd. : Member NSE – ID 09391, SEBI Registration No. NSE CM Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE FO Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE CDS Segment INZ000202536, Member NSE Commodity – ID 09391, SEBI Registration No. NSE COMMODITY Segment Exchange Registered Broker, Member MSEI – ID 1067, SEBI Registration No. MSEI CM Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI FO Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI CDS Segment INZ000202536, Member MCX – ID 56460, SEBI Registration No. MCX COMMODITY Segment INZ000202536, Member NCDEX – ID 1268, SEBI Registration No. NCDEX COMMODITY Segment INZ000202536, Member ICEX – ID 2073, SEBI Registration No. ICEX COMMODITY Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CM Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE FO Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CDS Segment Exchange Registered Broker, Member BSE Commodity – ID 0498, SEBI Registration No. BSE COMMODITY Segment Exchange Registered Broker, SEBI Registration No. PMS INP000002981, SEBI Registration No. Research Analyst INP000002981, SEBI Registration No. DP Participants NSDL – CDSL IN-DP-CDSL 37-99,Member Comtrack Participant Id – ID 50274, Member NERL RP Id– ID R1447, Nirmal Bang Equities Private Limited Member BSE – ID 245, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. NSE FO Segment INZ000186135, Member NSE Currency – ID 13437, SEBI Registration No. NSE CDS Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI CM Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI FO Segment INZ000186135, SEBI Registration No. Research Analyst Segment INH000001436, Nirmal Bang Commodities Private Limited Member MCX – ID 16590, SEBI Registration No. MCX COMMODITY Segment INZ000043630, Member NCDEX – ID 00362, SEBI Registration No. NCDEX COMMODITY Segment INZ000043630, Member ICEX – ID 1165, SEBI Registration No. ICEX COMMODITY Segment INZ000043630, Member NCDEX Spot Exchange – ID 10084,Comtrack Participant CPID -5040, Participant CDSL Commodity Repository Limited - 12013300
For any grievances, please get in touch on 022-62739390 and write a mail to Contact@nirmalbang.com with Subject line as Grievances/Complain.     |    

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

AppleApp Store GooglePlay Store
AppleApp StoreGooglePlay Store
Support
Videos
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.